Petlife Pharmaceuticals, Inc. (PTLF) Financial Statements (2024 and earlier)
Company Profile
Business Address |
10120 SO. EASTERN AVENUE, HENDERSON,, NV 89052 |
State of Incorp. | NV |
Fiscal Year End | August 31 |
Industry (SIC) | 286 - Industrial Organic Chemicals (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)Annual | Quarterly
2/28/2018 Q2 | 11/30/2017 Q1 | 8/31/2017 Q4 | 5/31/2017 Q3 | 2/28/2017 Q2 | 11/30/2016 Q1 | 8/31/2016 Q4 | |||
---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
Current Assets | |||||||||
Cash, cash equivalents, and short-term investments | 54,312 | 54,254 | 321 | 445 | 28,996 | 1,172 | |||
Cash and cash equivalents | 54,312 | 54,254 | 321 | 445 | 28,996 | 1,172 | |||
Inventory, net of allowances, customer advances and progress billings | 17,915 | 17,915 | |||||||
Inventory | 17,915 | 17,915 | |||||||
Prepaid expense | 3,329 | 750 | 212,933 | ||||||
Other undisclosed current assets | (17,915) | ||||||||
Total current assets: | 57,641 | 55,004 | 18,236 | 213,378 | 28,996 | 1,172 | |||
Noncurrent Assets | |||||||||
Intangible assets, net (including goodwill) | 252,085 | ||||||||
Intangible assets, net (excluding goodwill) | 252,085 | ||||||||
Total noncurrent assets: | 252,085 | ||||||||
TOTAL ASSETS: | 57,641 | 55,004 | 270,321 | 213,378 | 28,996 | 1,172 | |||
LIABILITIES AND EQUITY | |||||||||
Liabilities | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities, including: | 511,965 | 531,375 | 415,085 | 350,000 | 513,713 | 291,547 | |||
Accounts payable | 290,068 | 307,478 | 335,867 | 370,290 | |||||
Accrued liabilities | 221,897 | 223,897 | 79,218 | 3,811 | |||||
Other undisclosed accounts payable and accrued liabilities | (24,101) | 513,713 | 291,547 | ||||||
Debt | 297,000 | 312,000 | 317,000 | 10,000 | 10,000 | ||||
Derivative instruments and hedges, liabilities | 447,626 | 102,377 | |||||||
Due to related parties | 10,000 | 10,000 | 10,000 | 309,193 | 150,000 | 10,000 | |||
Other undisclosed current liabilities | 563,411 | 480,702 | 850,270 | 456,601 | 3,500,457 | 2,934,485 | |||
Total current liabilities: | 1,830,002 | 1,436,454 | 1,592,355 | 1,125,794 | 4,174,170 | 3,236,032 | |||
Noncurrent Liabilities | |||||||||
Total liabilities: | 1,830,002 | 1,436,454 | 1,592,355 | 1,125,794 | 4,174,170 | 3,236,032 | |||
Equity | |||||||||
Equity, attributable to parent | (1,772,361) | (1,381,450) | (1,322,034) | (912,416) | (4,145,174) | (3,234,860) | |||
Preferred stock | 3,250 | 3,250 | |||||||
Common stock | 73,951 | 73,842 | 69,508 | 62,304 | 43,853 | 8,400 | |||
Additional paid in capital | 29,005,278 | 28,929,638 | 26,997,219 | 26,599,024 | 22,057,935 | 3,888,070 | |||
Accumulated deficit | (30,854,840) | (30,388,180) | (28,388,761) | (27,573,744) | (26,246,962) | (7,131,330) | |||
Total equity: | (1,772,361) | (1,381,450) | (1,322,034) | (912,416) | (4,145,174) | (3,234,860) | |||
TOTAL LIABILITIES AND EQUITY: | 57,641 | 55,004 | 270,321 | 213,378 | 28,996 | 1,172 |
Income Statement (P&L) (USD)Annual | Quarterly
2/28/2018 Q2 | 11/30/2017 Q1 | 8/31/2017 Q4 | 5/31/2017 Q3 | 2/28/2017 Q2 | 11/30/2016 Q1 | 8/31/2016 Q4 | ||
---|---|---|---|---|---|---|---|---|
Operating expenses | (117,559) | (1,037,427) | (142,897) | (42,202) | (19,113,466) | (3,322,410) | ||
Other undisclosed operating loss | (75,749) | (677,568) | (429,083) | (1,212,735) | ||||
Operating loss: | (193,308) | (1,714,995) | (571,980) | (1,254,937) | (19,113,466) | (3,322,410) | ||
Interest and debt expense | (86,893) | (577,382) | (3,937) | (11,844) | (2,166) | |||
Loss from continuing operations: | (280,201) | (2,292,377) | (575,917) | (1,266,781) | (19,115,632) | (3,322,410) | ||
Loss before gain (loss) on sale of properties: | (280,201) | (2,292,377) | (575,917) | (1,266,781) | (19,115,632) | (3,322,410) | ||
Net loss: | (280,201) | (2,292,377) | (575,917) | (1,266,781) | (19,115,632) | (3,322,410) | ||
Other undisclosed net income (loss) attributable to parent | (186,459) | 292,958 | (239,100) | (50,000) | ||||
Net loss available to common stockholders, diluted: | (466,660) | (1,999,419) | (815,017) | (1,316,781) | (19,115,632) | (3,322,410) |
Comprehensive Income (USD)Annual | Quarterly
2/28/2018 Q2 | 11/30/2017 Q1 | 8/31/2017 Q4 | 5/31/2017 Q3 | 2/28/2017 Q2 | 11/30/2016 Q1 | 8/31/2016 Q4 | ||
---|---|---|---|---|---|---|---|---|
Net loss: | (280,201) | (2,292,377) | (575,917) | (1,266,781) | (19,115,632) | (3,322,410) | ||
Comprehensive loss, net of tax, attributable to parent: | (280,201) | (2,292,377) | (575,917) | (1,266,781) | (19,115,632) | (3,322,410) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.